1. Home
  2. ELBM vs XLO Comparison

ELBM vs XLO Comparison

Compare ELBM & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Electra Battery Materials Corporation

ELBM

Electra Battery Materials Corporation

N/A

Current Price

$0.58

Market Cap

54.9M

Sector

Miscellaneous

ML Signal

N/A

XLO

Xilio Therapeutics Inc.

N/A

Current Price

$9.50

Market Cap

56.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ELBM
XLO
Founded
2011
2016
Country
Canada
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.9M
56.9M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
ELBM
XLO
Price
$0.58
$9.50
Analyst Decision
Strong Buy
Buy
Analyst Count
2
1
Target Price
$2.15
$28.00
AVG Volume (30 Days)
341.2K
18.1K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,766,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$28.71
$168.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
589.88
52 Week Low
$0.49
$0.46
52 Week High
$8.70
$9.90

Technical Indicators

Market Signals
Indicator
ELBM
XLO
Relative Strength Index (RSI) 50.54 61.36
Support Level $0.56 $7.47
Resistance Level $0.60 $9.75
Average True Range (ATR) 0.04 0.42
MACD 0.00 0.03
Stochastic Oscillator 51.97 62.57

Price Performance

Historical Comparison
ELBM
XLO

About ELBM Electra Battery Materials Corporation

Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry. The Company's operating segments are Refinery, Exploration and Evaluation, Corporate and Other.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: